Viking Therapeutics Inc (VKTX)
78.66
+3.24
(+4.30%)
USD |
NASDAQ |
Apr 30, 13:57
Viking Therapeutics Shareholders Equity (Quarterly): 933.89M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 933.89M |
December 31, 2023 | 348.42M |
September 30, 2023 | 368.24M |
June 30, 2023 | 386.12M |
March 31, 2023 | 134.06M |
December 31, 2022 | 145.32M |
September 30, 2022 | 151.28M |
June 30, 2022 | 165.23M |
March 31, 2022 | 182.27M |
December 31, 2021 | 201.88M |
September 30, 2021 | 213.12M |
June 30, 2021 | 224.97M |
March 31, 2021 | 237.22M |
December 31, 2020 | 244.34M |
September 30, 2020 | 253.79M |
June 30, 2020 | 261.95M |
March 31, 2020 | 268.28M |
December 31, 2019 | 277.12M |
September 30, 2019 | 283.49M |
June 30, 2019 | 288.35M |
Date | Value |
---|---|
March 31, 2019 | 294.57M |
December 31, 2018 | 297.75M |
September 30, 2018 | 302.05M |
June 30, 2018 | 140.36M |
March 31, 2018 | 72.63M |
December 31, 2017 | 13.46M |
September 30, 2017 | 2.226M |
June 30, 2017 | 6.588M |
March 31, 2017 | 7.546M |
December 31, 2016 | 8.043M |
September 30, 2016 | 10.22M |
June 30, 2016 | 12.79M |
March 31, 2016 | 5.770M |
December 31, 2015 | 8.725M |
September 30, 2015 | 13.27M |
June 30, 2015 | 17.39M |
March 31, 2015 | -27.84M |
December 31, 2014 | -22.13M |
June 30, 2014 | -23.26M |
March 31, 2014 | -0.4786M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
134.06M
Minimum
Mar 2023
933.89M
Maximum
Mar 2024
278.47M
Average
249.07M
Median
Shareholders Equity (Quarterly) Benchmarks
Eli Lilly and Co | 10.77B |
Pfizer Inc | 89.01B |
Madrigal Pharmaceuticals Inc | 405.33M |
Akero Therapeutics Inc | 535.31M |
Terns Pharmaceuticals Inc | 255.37M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 967.52M |
Total Liabilities (Quarterly) | 33.63M |